CIA
CORT icon

Capital Impact Advisors’s Corcept Therapeutics CORT Stock Holding History

Capital Impact Advisors’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-26,537
Closed -$668K – 61
2024
Q1 		$668K Buy
+26,537
New +$627K 0.87% 48
2022
Q1 		– Sell
-72,794
Closed -$1.44M – 190
2021
Q4 		$1.44M Sell
72,794
-45,290
-38% -$919K 0.99% 37
2021
Q3 		$2.32M Hold
118,084
– – 0.92% 45
2021
Q2 		$2.6M Sell
118,084
-50,000
-30% -$1.11M 0.84% 50
2021
Q1 		$4M Sell
168,084
-9,216
-5% -$246K 1.4% 21
2020
Q4 		$4.64M Hold
177,300
– – 1.14% 29
2020
Q3 		$3.09M Hold
177,300
– – 0.91% 36
2020
Q2 		$2.98M Hold
177,300
– – 1% 30
2020
Q1 		$2.11M Buy
177,300
+7,312
+4% +$90.5K 0.89% 45
2019
Q4 		$2.06M Buy
169,988
+7,444
+5% +$104K 0.72% 76
2019
Q3 		$2.37M Sell
162,544
-20,926
-11% -$257K 0.9% 24
2019
Q2 		$2.04M Sell
183,470
-10,224
-5% -$114K 0.75% 45
2019
Q1 		$2.52M Hold
193,694
– – 1.12% 14
2018
Q4 		$2.52M Buy
193,694
+40,705
+27% +$538K 1.08% 15
2018
Q3 		$2.1M Buy
152,989
+35,550
+30% +$497K 0.72% 54
2018
Q2 		$1.85M Buy
117,439
+43,141
+58% +$751K 0.69% 59
2018
Q1 		$1.22M Sell
74,298
-3,896
-5% -$72.2K 0.5% 108
2017
Q4 		$1.41M Hold
78,194
– – 0.61% 77
2017
Q3 		$1.51M Hold
78,194
– – 0.67% 54
2017
Q2 		$923K Sell
78,194
-29,956
-28% -$326K 0.42% 125
2017
Q1 		$1.19M Buy
+108,150
New +$950K 0.47% 119
2015
Q1 		– Sell
-59,735
Closed -$179K – 272
2014
Q4 		$179K Buy
59,735
+59,675
+99,458% +$182K 0.08% 135
2014
Q3 		$160 Sell
60
-59,675
-100% -$158K ﹤0.01% 122
2014
Q2 		$167K Buy
+59,735
New +$176K 0.13% 141

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return

Capital Impact Advisors's CORT Position: Q2 2024 in Review

Capital Impact Advisors sold out of Corcept Therapeutics (CORT) in Q2 2024, closing a stake of 26,537 shares — an estimated $668K sold.

Capital Impact Advisors first reported a position in CORT in Q2 2014 and held it in 24 quarters. The position peaked at $4.64M in Q4 2020. 286 funds tracked by Wall St. Rank hold CORT as of Q2 2024.

  • Capital Impact Advisors reported no remaining Corcept Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Capital Impact Advisors sold 26,537 Corcept Therapeutics shares in Q2 2024, an estimated $668K.
  • Capital Impact Advisors first reported a position in Corcept Therapeutics in Q2 2014 and held it in 24 quarters.
  • Capital Impact Advisors's Corcept Therapeutics position peaked at $4.64M in Q4 2020.
  • 286 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2024.

Based on Capital Impact Advisors's 13F filing for Q2 2024, filed 16 Aug 2024.